The purpose of this study is to find out more about darbepoetin alfa in children less than 1 year of age with anemia (a decrease in red blood cells) due to kidney failure. This study will see if darbepoetin alfa is safe and well tolerated and whether it causes any side effects by taking blood samples and checking vital signs (heart rate, body temperature, and blood pressure tests) at specific times throughout the study. In addition, the study will evaluate the amount of darbepoetin alfa in the blood over time and look at special markers in the blood to evaluate how darbepoetin alfa works on anemia. Darbepoetin alfa is approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) for use in adults, but not for all ages of pediatric subjects. Therefore, studies need to be conducted in pediatric subjects (children) to determine the appropriate dose to use in younger children.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
Number of subjects with clinically significant changes in physical examinations, laboratory safety tests, and vital signs
Time frame: Assessed over 29 days
Number of subjects with treatment-emergent adverse events
Time frame: Assessed over 29 days
Maximum observed concentration (Cmax) of darbepoetin alfa
Time frame: Assessed predose and at 6, 24, 48, 72, and 168 hours postdose
Time at which maximum concentration is observed (Tmax) of darbepoetin alfa
Time frame: Assessed predose and at 6, 24, 48, 72, and 168 hours postdose
Area under the concentration curve (AUC) of darbepoetin alfa
Time frame: Assessed predose and at 6, 24, 48, 72, and 168 hours postdose
Terminal half-life (t½) of darbepoetin alfa
Time frame: Assessed predose and at 6, 24, 48, 72, and 168 hours postdose
Clearance (CL) of darbepoetin alfa
Time frame: Assessed predose and at 6, 24, 48, 72, and 168 hours postdose
Change in reticulocytes
Time frame: Assessed from baseline to day 8
Change in reticulocytes
Time frame: Assessed from baseline to day 29
Change in hemoglobin concentration
Time frame: Assessed from baseline to day 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in hemoglobin concentration
Time frame: Assessed from baseline to day 29
Change in iron
Time frame: Assessed from baseline to day 29
Change in ferritin
Time frame: Assessed from baseline to day 29
Change in transferrin saturation
Time frame: Assessed from baseline to day 29